Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas release_vftur3qhena6dho7kznwyo5kbu

by David Viskochil, Mariusz Wysocki, Maria Learoyd, Peng Sun, Karen So, Azura Evans, Francis Lai, Héctor Salvador Hernàndez

Published in Neuro-Oncology Advances by Oxford University Press (OUP).

2024   Volume 6, Issue 1, vdae036

Abstract

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> Selumetinib is approved for the treatment of pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) in multiple countries, including the USA (≥2 years). Until recently, individuals had to take selumetinib twice daily (BID) in a fasted state. This study evaluated the effect of a low-fat meal on selumetinib PK parameters and gastrointestinal (GI) tolerability in adolescent participants with NF1-PN. </jats:sec> <jats:sec> <jats:title>Methods</jats:title> Eligible participants aged ≥12–&amp;lt;18 years took 25 mg/m2 selumetinib BID with a low-fat meal (T1) for 28 days, followed by a 7-day washout, and then administration in a fasted state (T2) for another 28 days. Primary objectives were to evaluate the effect of a low-fat meal on AUC0−12,ss and GI tolerability after multiple selumetinib doses in T1 versus T2. Key secondary objectives were additional PK parameters, and adverse events (AEs). </jats:sec> <jats:sec> <jats:title>Results</jats:title> At primary data cut-off, all 24 participants completed T1, and 23 participants completed T2. There were no significant differences in AUC0−12,ss between T1 and T2. In T1 and T2, 29.2% and 33.3% participants, respectively, reported ≥1 GI AE. No GI AEs Grade ≥3, or serious AEs, or GI AEs resulting in treatment interruptions, discontinuation, or dose reductions were reported in T1 and T2. </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> Dosing selumetinib with a low-fat meal had no clinically relevant impact on selumetinib AUC0−12,ss nor GI tolerability in adolescents with NF1-PN. </jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf   900.4 kB
file_jcek6jcsmjbqxcsg3pfxwhl5wq
watermark.silverchair.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2024-03-16
Language   en ?
Journal Metadata
Open Access Publication
In DOAJ
In Keepers Registry
ISSN-L:  2632-2498
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: de4cb232-14c8-4e98-a837-cee0c8ae10f3
API URL: JSON